The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings

Thu, 30th Nov 2023 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Ashtead Technology Holdings PLC, up 20% at 582.00 pence, 12-month range 281.00p-594.00p. The subsea equipment rental, serving the offshore energy sector, says it now expects 2023 results to be "comfortably ahead of its previous expectations". It also announces a GBP53.5 million deal to acquire ACE Winches, from that firm's founders Alfie and Valerie Cheyne. ACE offers lifting, pulling and deployment services, and will sit nicely with "Ashtead Technology's existing equipment and services portfolio", it says.

----------

AIM - LOSERS

----------

Proteome Sciences PLC, down 25% at 4.54p, 12-month range 3.15p-8.79p. The protein-focused drug development services provider cuts its revenue outlook for 2023 amid delays to projects. It expects its top line to shrink from 2022's GBP7.8 million. "As reported by many other life science technology providers, the company has experienced delays to projects, many of which have been postponed to 2024. The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year," Proteome Sciences explains. Proteome adds that reduced revenue combined with its commitment to invest in a US lab, means its now expects to post a net loss for 2023. In 2022, the company posted a profit after tax of GBP1.3 million. Proteome says it expects its US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory.

----------

Totally PLC, down 16% at 4.85p, 12-month range 4.80p-38.00p. A poor week for the stock continues and it looks likely to suffer a fourth-successive share price decline. On Tuesday, the healthcare services provider in UK and Ireland reported that it swung to a pretax loss of GBP1.9 million in the first half ended September 30, from a profit of GBP1.0 million the year prior. Revenue fell 21% to GBP55.8 million during the period, from GBP70.3 million a year ago, Totally said. The firm blamed a "crisis" faced by the UK NHS for the lower revenue, given the loss of its North West London contracts. Shares have fallen 48% so far this week and it hit this 12-month low on Thursday.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
26 Apr 2024 11:18

Proteome wins GBP500,000 deal to supply mass spectrometry services

(Alliance News) - Proteome Sciences PLC on Friday said it won a contract from an unnamed US biopharmaceutical company to use Proteome's mass spectrome...

26 Apr 2024 10:40

AIM WINNERS & LOSERS: Proteome Sciences rises on GBP500,000 contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

26 Apr 2024 09:45

Proteome Sciences secures contract win with US biopharmaceutical firm

(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's ma...

26 Apr 2024 09:14

LONDON MARKET OPEN: Thoma Bravo snaps up Darktrace for USD5 billion

(Alliance News) - Stock prices in London opened higher on Friday, as investors shook off nerves ahead of US inflation data this afternoon.

10 Apr 2024 11:26

Proteome Sciences shares drop as revenue plunges and swings to loss

(Alliance News) - Proteome Sciences PLC on Wednesday said it swung to a loss in 2023 on higher costs, and saw its revenue plunge on contract delays.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.